

Report MQ 2024/4 Microbiology: Antibody and antigen tests

Summary

| Sample | Results | Good | % Good |
|-----------------------------------|-------------|-------------|--------------|
| B01 Strep A Antigen | 1236 | 1217 | 98.46 |
| B04 Rubella / Mumps IgG/IgM | 84 | 83 | 98.81 |
| B05 Toxoplasmosis IgG/IgM | 50 | 49 | 98.00 |
| B06 Lues / syphilis serology | 73 | 72 | 98.63 |
| B07 Cytomegalovirus IgG/IgM | 71 | 71 | 100.00 |
| B08 Varicella / HSV1/2 IgG/IgM | 93 | 90 | 96.77 |
| B20 Epstein-Barr-Virus IgG/IgM | 169 | 164 | 97.04 |
| B21 Legionella antigen urine | 76 | 76 | 100.00 |
| B22 S. pneumoniae antigen urine | 63 | 63 | 100.00 |
| B24 RSV/Influenza rapid test | 26 | 26 | 100.00 |
| B27 Helicobacter Pylori Antigen | 64 | 62 | 96.88 |
| B30 Rota-/Adeno-/Norovirus Ag | 75 | 73 | 97.33 |
| B32 SARS-CoV-2 IgG/IgM | 17 | 17 | 100.00 |
| B33 SARS-CoV-2 Ag | 38 | 38 | 100.00 |
| B34 FSME IgG/IgM | 8 | 8 | 100.00 |
| B35 Masern/Parvovirus IgG/IgM | 40 | 38 | 95.00 |
| B37 C. Diff Ag (GDH, Toxin A/B) | 57 | 57 | 100.00 |
| B38 H. pylori Urease-Test | 4 | 4 | 100.00 |
| B39 Mycobacteria, microscopy | 54 | 54 | 100.00 |
| B42 HIV, Hepatitis B/C, Serologie | 425 | 424 | 99.76 |
| B43 Hepatitis A IgG / IgM | 69 | 69 | 100.00 |
| B44 Hepatitis E IgG / IgM | 22 | 22 | 100.00 |
| H11 Malaria rapid test / NAT | 92 | 92 | 100.00 |
| V01 HIV Schnelltest | 24 | 22 | 91.67 |
| Total | 2930 | 2891 | 98.67 |

B01 Strep A Antigen

| Strep A | Target Value | negative | positive | % Conform |
|----------------|---------------------|-----------------|-----------------|------------------|
| Rapid Test | negative | 1217 | 19 | 98.46 |

Commentary B01

The correct result was "Strep-A negative".

B04 Rubella / Mumps IgG/IgM

| Rubella IgG | Target Value | negative | positive | % Conform |
|--------------------|--------------|----------|----------|-----------|
| all Participants | positive | 1 | 37 | 97.37 |

| Rubella IgM | Target Value | negative | positive | % Conform |
|--------------------|--------------|----------|----------|-----------|
| all Participants | negative | 32 | 0 | 100.00 |

| Mumps IgG | Target Value | negative | positive | % Conform |
|------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 8 | 100.00 |

| Mumps IgM | Target Value | negative | positive | % Conform |
|------------------|--------------|----------|----------|-----------|
| all Participants | negative | 6 | 0 | 100.00 |

B05 Toxoplasmosis IgG/IgM

| Toxoplasma IgG | Target Value | negative | border | positive | % Conform |
|-----------------------|--------------|----------|----------|-----------|---------------|
| Abbott | positive | 0 | 0 | 6 | 100.00 |
| Roche, Cobas | positive | 0 | 0 | 11 | 100.00 |
| Other methods | positive | 0 | 0 | 8 | 100.00 |
| Total | | 0 | 0 | 25 | 100.00 |

| Toxoplasma IgM | Target Value | negative | border | positive | % Conform |
|-----------------------|----------------|----------|----------|-----------|--------------|
| Abbott | positive | 0 | 0 | 6 | 100.00 |
| Roche, Cobas | positive | 1 | 0 | 10 | 90.91 |
| Other methods | Borderline/pos | 0 | 1 | 7 | 100.00 |
| Total | | 1 | 1 | 23 | 96.00 |

B06 Lues / syphilis serology

| Syphilis TPPA | Target Value | negative | positive | % Conform |
|----------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 15 | 100.00 |

| Treponema IgG | Target Value | negative | positive | % Conform |
|----------------------|--------------|----------|----------|-----------|
| EIA | positive | 0 | 7 | 100.00 |

| Treponema IgM | Target Value | negative | positive | % Conform |
|----------------------|--------------|----------|----------|---------------|
| Immunoblot | negative | 1 | 0 | 100.00 |
| EIA | not rateable | 2 | 3 | 100.00 |
| Total | | 3 | 3 | 100.00 |

| RPR/VDRL | Target Value | negative | positive | % Conform |
|------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 20 | 100.00 |

| Treponema Screening (Ig total) | Target Value | negative | positive | % Conform |
|---------------------------------------|--------------|----------|----------|-----------|
| all Participants | positive | 1 | 15 | 93.75 |

| Treponema TPHA | Target Value | negative | positive | % Conform |
|-----------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 9 | 100.00 |

B07 Cytomegalovirus IgG/IgM

| Cytomegaly IgG | Target Value | negative | positive | % Conform |
|-----------------------|--------------|----------|-----------|---------------|
| Abbott | positive | 0 | 10 | 100.00 |
| Roche, Cobas | positive | 0 | 16 | 100.00 |
| Other methods | positive | 0 | 11 | 100.00 |
| Total | | 0 | 37 | 100.00 |

| Cytomegaly IgM | Target Value | negative | positive | % Conform |
|-----------------------|--------------|-----------|----------|---------------|
| Abbott | negative | 9 | 0 | 100.00 |
| Roche, Cobas | negative | 14 | 0 | 100.00 |
| Other methods | negative | 11 | 0 | 100.00 |
| Total | | 34 | 0 | 100.00 |

B08 Varicella / HSV1/2 IgG/IgM

| Varicellen IgG | Target Value | negative | positive | % Conform |
|-----------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 35 | 100.00 |

| Varicellen IgM | Target Value | negative | positive | % Conform |
|-----------------------|--------------|----------|----------|-----------|
| all Participants | negative | 23 | 0 | 100.00 |

| HSV 1/2 IgG | Target Value | negative | positive | % Conform |
|--------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 3 | 100.00 |

| HSV1 IgG | Target Value | negative | positive | % Conform |
|------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 10 | 100.00 |

| HSV2 IgG | Target Value | negative | positive | % Conform |
|------------------|--------------|----------|----------|-----------|
| all Participants | negative | 10 | 0 | 100.00 |

| HSV1/2 IgM | Target Value | negative | positive | % Conform |
|-------------------|--------------|----------|----------|-----------|
| all Participants | positive | 3 | 9 | 75.00 |

B20 Epstein-Barr-Virus IgG/IgM

| EBV heterophilic antibodies | Target Value | negative | positive | % Conform |
|------------------------------------|--------------|----------|----------|-----------|
| Rapid Test | negative | 63 | 5 | 92.65 |

| EBV EBNA-1 IgG | Target Value | negative | positive | % Conform |
|-----------------------|--------------|----------|-----------|---------------|
| Abbott | positive | 0 | 6 | 100.00 |
| Liaison | positive | 0 | 7 | 100.00 |
| VIDAS | positive | 0 | 6 | 100.00 |
| Other methods | positive | 0 | 14 | 100.00 |
| Total | | 0 | 33 | 100.00 |

| EBV VCA-IgG | Target Value | negative | positive | % Conform |
|--------------------|--------------|----------|-----------|---------------|
| Abbott | positive | 0 | 7 | 100.00 |
| Liaison | positive | 0 | 7 | 100.00 |
| VIDAS | positive | 0 | 6 | 100.00 |
| Other methods | positive | 0 | 14 | 100.00 |
| Total | | 0 | 34 | 100.00 |

| EBV VCA-IgM | Target Value | negative | positive | % Conform |
|--------------------|--------------|-----------|----------|---------------|
| Abbott | negative | 6 | 0 | 100.00 |
| Liaison | negative | 7 | 0 | 100.00 |
| VIDAS | negative | 6 | 0 | 100.00 |
| Other methods | negative | 15 | 0 | 100.00 |
| Total | | 34 | 0 | 100.00 |

B21 Legionella antigen urine

| Legionella antigen urine | Target Value | negative | positive | % Conform |
|---------------------------------|---------------------|-----------------|-----------------|------------------|
| Quidel Sofia | negative | 19 | 0 | 100.00 |
| BinaxNOW | negative | 33 | 0 | 100.00 |
| Other methods | negative | 24 | 0 | 100.00 |
| Total | | 76 | 0 | 100.00 |

B22 S. pneumoniae antigen urine

| S. pneumoniae antigen urine | Target Value | negative | positive | % Conform |
|------------------------------------|---------------------|-----------------|-----------------|------------------|
| Quidel Sofia | negative | 18 | 0 | 100.00 |
| BinaxNOW | negative | 25 | 0 | 100.00 |
| Other methods | negative | 20 | 0 | 100.00 |
| Total | | 63 | 0 | 100.00 |

B24 RSV/Influenza rapid test

| RSV Antigen | Target Value | negative | positive | % Conform |
|--------------------|--------------|-----------|----------|---------------|
| BinaxNOW | negative | 3 | 0 | 100.00 |
| Other methods | negative | 13 | 0 | 100.00 |
| Total | | 16 | 0 | 100.00 |

| Influenza Ag | Target Value | negative | positive | % Conform |
|---------------------|--------------|----------|----------|-----------|
| Other methods | negative | 10 | 0 | 100.00 |

B27 Helicobacter Pylori Antigen

| Helicobacter pylori antigen | Target Value | negative | positive | % Conform |
|------------------------------------|---------------------|-----------------|-----------------|------------------|
| Rapid Test | negative | 22 | 0 | 100.00 |
| Meridian STAT! HpSA | negative | 4 | 2 | 66.67 |
| Ridascreen | negative | 6 | 0 | 100.00 |
| SD-Biosensor | negative | 3 | 0 | 100.00 |
| Liaison | negative | 10 | 0 | 100.00 |
| CerTest Biotec | negative | 12 | 0 | 100.00 |
| Oxoid RAPID Hp StAR | negative | 5 | 0 | 100.00 |
| Total | | 62 | 2 | 96.88 |

B30 Rota-/Adeno-/Norovirus Ag

| Rotavirus Ag | Target Value | negative | positive | % Conform |
|---------------------|--------------|-----------|----------|--------------|
| SD-Biosensor | negative | 5 | 0 | 100.00 |
| CerTest Biotec | negative | 4 | 2 | 66.67 |
| r-biopharm | negative | 5 | 0 | 100.00 |
| Other methods | negative | 17 | 0 | 100.00 |
| Total | | 31 | 2 | 93.94 |

| Adenovirus Ag | Target Value | negative | positive | % Conform |
|----------------------|--------------|-----------|----------|---------------|
| SD-Biosensor | negative | 5 | 0 | 100.00 |
| CerTest Biotec | negative | 5 | 0 | 100.00 |
| r-biopharm | negative | 5 | 0 | 100.00 |
| Other methods | negative | 18 | 0 | 100.00 |
| Total | | 33 | 0 | 100.00 |

| Norovirus Ag | Target Value | negative | positive | % Conform |
|---------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 9 | 100.00 |

B32 SARS-CoV-2 IgG/IgM

| SARS-CoV-2 IgG/A/M | Target Value | negative | positive | % Conform |
|---------------------------|--------------|----------|----------|---------------|
| all Participants | negative | 1 | 0 | 100.00 |
| Roche, Cobas | positive | 0 | 1 | 100.00 |
| Total | | 1 | 1 | 100.00 |

| SARS-CoV-2 IgG | Target Value | negative | positive | % Conform |
|-----------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 4 | 100.00 |

| SARS-CoV-2 IgM | Target Value | negative | positive | % Conform |
|-----------------------|--------------|----------|----------|-----------|
| all Participants | negative | 1 | 0 | 100.00 |

| SARS-CoV-2 IgG Spike 1 | Target Value | negative | positive | % Conform |
|-------------------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 6 | 100.00 |

| SARS-CoV-2 IgG NCP | Target Value | negative | positive | % Conform |
|---------------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 2 | 100.00 |

| SARS-CoV-2 IgG Spike 2 Ak | Target Value | negative | positive | % Conform |
|----------------------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 2 | 100.00 |

B33 SARS-CoV-2 Ag

| SARS-CoV-2 Antigen | Target Value | negative | positive | % Conform |
|---------------------------|---------------------|-----------------|-----------------|------------------|
| Roche | negative | 16 | 0 | 100.00 |
| Other methods | negative | 22 | 0 | 100.00 |
| Total | | 38 | 0 | 100.00 |

B34 FSME IgG/IgM

| FSME IgG | Target Value | negative | border | positive | % Conform |
|------------------|--------------|----------|--------|----------|-----------|
| all Participants | positive | 0 | 0 | 4 | 100.00 |

| FSME IgM | Target Value | negative | border | positive | % Conform |
|------------------|----------------|----------|--------|----------|-----------|
| all Participants | Borderline/neg | 3 | 1 | 0 | 100.00 |

B35 Masern/Parvovirus IgG/IgM

| Masern IgG | Target Value | negative | border | positive | % Conform |
|-------------------|--------------|----------|--------|----------|-----------|
| all Participants | positive | 0 | 0 | 12 | 100.00 |

| Masern IgM | Target Value | negative | border | positive | % Conform |
|-------------------|--------------|----------|--------|----------|-----------|
| all Participants | negative | 8 | 0 | 0 | 100.00 |

| Parvovirus B19 IgG | Target Value | negative | border | positive | % Conform |
|---------------------------|--------------|----------|--------|----------|-----------|
| all Participants | negative | 10 | 0 | 0 | 100.00 |

| Parvovirus B19 IgM | Target Value | negative | border | positive | % Conform |
|---------------------------|----------------|----------|--------|----------|-----------|
| all Participants | Borderline/pos | 2 | 1 | 7 | 80.00 |

B37 C. Diff Ag (GDH, Toxin A/B)

| C. Diff GDH | Target Value | negative | positive | % Conform |
|---------------------------|--------------|----------|-----------|---------------|
| Ridascreen | positive | 0 | 4 | 100.00 |
| all Participants | positive | 0 | 11 | 100.00 |
| Techlab C.Diff Quick Chek | positive | 0 | 11 | 100.00 |
| Total | | 0 | 26 | 100.00 |

| C. Diff Toxin A | Target Value | negative | positive | % Conform |
|------------------------|--------------|----------|----------|-----------|
| all Participants | negative | 5 | 0 | 100.00 |

| C. Diff Toxin B | Target Value | negative | positive | % Conform |
|------------------------|--------------|----------|----------|-----------|
| all Participants | negative | 5 | 0 | 100.00 |

| C. Diff Tox A/B | Target Value | negative | positive | % Conform |
|---------------------------|--------------|-----------|----------|---------------|
| Other methods | negative | 5 | 0 | 100.00 |
| Ridascreen | negative | 4 | 0 | 100.00 |
| Techlab C.Diff Quick Chek | negative | 12 | 0 | 100.00 |
| Total | | 21 | 0 | 100.00 |

B38 H. pylori Urease-Test

| H. pylori Urease-Test | Target Value | negative | positive | % Conform |
|------------------------------|---------------------|-----------------|-----------------|------------------|
| Rapid Test | positive | 0 | 4 | 100.00 |

B39 Mycobacteria, microscopy

| Acid-fast bacilli A | Target Value | negative | positive | % Conform |
|----------------------------|--------------|----------|-----------|---------------|
| Ziehl-Neelsen | positive | 0 | 23 | 100.00 |
| Auramin-Rhodamin | positive | 0 | 4 | 100.00 |
| Total | | 0 | 27 | 100.00 |

| Acid-fast bacilli B | Target Value | negative | positive | % Conform |
|----------------------------|--------------|----------|-----------|---------------|
| Ziehl-Neelsen | positive | 0 | 23 | 100.00 |
| Auramin-Rhodamin | positive | 0 | 4 | 100.00 |
| Total | | 0 | 27 | 100.00 |

B42 HIV, Hepatitis B/C, Serologie

| HIV 1/2 Combo sample A | Target Value | negative | border | positive | % Conform |
|-------------------------------|--------------|----------|----------|-----------|---------------|
| Abbott | positive | 0 | 0 | 12 | 100.00 |
| Roche, Cobas | positive | 0 | 0 | 19 | 100.00 |
| Other methods | positive | 0 | 0 | 6 | 100.00 |
| Total | | 0 | 0 | 37 | 100.00 |

| HIV 1/2 ig sample A | Target Value | negative | border | positive | % Conform |
|----------------------------|--------------|----------|--------|----------|-----------|
| Roche, Cobas | positive | 0 | 0 | 1 | 100.00 |

| HBs Ig sample A | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 10 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 14 | 0 | 0 | 100.00 |
| Other methods | negative | 6 | 0 | 0 | 100.00 |
| Total | | 30 | 0 | 0 | 100.00 |

| HBs Ag sample A | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 10 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 15 | 0 | 0 | 100.00 |
| Other methods | negative | 6 | 0 | 0 | 100.00 |
| Total | | 31 | 0 | 0 | 100.00 |

| HBc Ig sample A | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 10 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 15 | 0 | 0 | 100.00 |
| Other methods | negative | 5 | 0 | 0 | 100.00 |
| Total | | 30 | 0 | 0 | 100.00 |

| HBc IgM sample A | Target Value | negative | border | positive | % Conform |
|-------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 8 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 4 | 0 | 0 | 100.00 |
| Other methods | negative | 4 | 0 | 0 | 100.00 |
| Total | | 16 | 0 | 0 | 100.00 |

| HBe Ig sample A | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 7 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 6 | 0 | 0 | 100.00 |
| Other methods | negative | 3 | 0 | 0 | 100.00 |
| Total | | 16 | 0 | 0 | 100.00 |

| HBe Ag sample A | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 8 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 6 | 0 | 0 | 100.00 |
| Other methods | negative | 3 | 0 | 0 | 100.00 |
| Total | | 17 | 0 | 0 | 100.00 |

| HCV Ig sample A | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 10 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 15 | 0 | 0 | 100.00 |
| Other methods | negative | 8 | 0 | 0 | 100.00 |
| Total | | 33 | 0 | 0 | 100.00 |

| HIV 1/2 Combo sample B | Target Value | negative | border | positive | % Conform |
|-------------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 12 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 19 | 0 | 0 | 100.00 |
| Other methods | negative | 6 | 0 | 0 | 100.00 |
| Total | | 37 | 0 | 0 | 100.00 |

| HIV 1/2 ig sample B | Target Value | negative | border | positive | % Conform |
|----------------------------|--------------|----------|--------|----------|-----------|
| Roche, Cobas | negative | 1 | 0 | 0 | 100.00 |

| HBs Ig sample B | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 10 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 15 | 0 | 0 | 100.00 |
| Other methods | negative | 6 | 0 | 0 | 100.00 |
| Total | | 31 | 0 | 0 | 100.00 |

| HBs Ag sample B | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|----------|----------|-----------|---------------|
| Abbott | positive | 0 | 0 | 10 | 100.00 |
| Roche, Cobas | positive | 0 | 0 | 15 | 100.00 |
| Other methods | positive | 0 | 0 | 6 | 100.00 |
| Total | | 0 | 0 | 31 | 100.00 |

| HBc Ig sample B | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 10 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 15 | 0 | 0 | 100.00 |
| Other methods | negative | 5 | 0 | 0 | 100.00 |
| Total | | 30 | 0 | 0 | 100.00 |

| HBc IgM sample B | Target Value | negative | border | positive | % Conform |
|-------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 8 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 6 | 0 | 0 | 100.00 |
| Other methods | negative | 4 | 0 | 0 | 100.00 |
| Total | | 18 | 0 | 0 | 100.00 |

| HBe Ig sample B | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|---------------|
| Abbott | negative | 7 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 6 | 0 | 0 | 100.00 |
| Other methods | negative | 3 | 0 | 0 | 100.00 |
| Total | | 16 | 0 | 0 | 100.00 |

| HBe Ag sample B | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|----------|----------|-----------|---------------|
| Abbott | positive | 0 | 0 | 8 | 100.00 |
| Roche, Cobas | positive | 0 | 0 | 6 | 100.00 |
| Other methods | positive | 0 | 0 | 3 | 100.00 |
| Total | | 0 | 0 | 17 | 100.00 |

| HCV Ig sample B | Target Value | negative | border | positive | % Conform |
|------------------------|--------------|-----------|----------|----------|--------------|
| Abbott | negative | 10 | 0 | 0 | 100.00 |
| Roche, Cobas | negative | 14 | 1 | 0 | 93.33 |
| Other methods | negative | 8 | 0 | 0 | 100.00 |
| Total | | 32 | 1 | 0 | 96.97 |

B43 Hepatitis A IgG / IgM

| HAV Ig | Target Value | negative | positive | % Conform |
|---------------|--------------|-----------|----------|---------------|
| Roche, Cobas | negative | 18 | 0 | 100.00 |
| Other methods | negative | 7 | 0 | 100.00 |
| Total | | 25 | 0 | 100.00 |

| HAV IgG | Target Value | negative | positive | % Conform |
|------------------|--------------|-----------|----------|---------------|
| all Participants | negative | 3 | 0 | 100.00 |
| Abbott | negative | 8 | 0 | 100.00 |
| Total | | 11 | 0 | 100.00 |

| HAV IgM | Target Value | negative | positive | % Conform |
|----------------|--------------|-----------|----------|---------------|
| Abbott | negative | 8 | 0 | 100.00 |
| Roche, Cobas | negative | 16 | 0 | 100.00 |
| Other methods | negative | 9 | 0 | 100.00 |
| Total | | 33 | 0 | 100.00 |

B44 Hepatitis E IgG / IgM

| HEV IgG | Target Value | negative | positive | % Conform |
|------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 11 | 100.00 |

| HEV IgM | Target Value | negative | positive | % Conform |
|------------------|--------------|----------|----------|-----------|
| all Participants | positive | 0 | 11 | 100.00 |

H11 Malaria rapid test / NAT

| Malaria | Target Value | negative | positive | % Conform |
|----------------|---------------------|-----------------|-----------------|------------------|
| Paramax | negative | 12 | 0 | 100.00 |
| BinaxNOW | negative | 35 | 0 | 100.00 |
| SD-Biosensor | negative | 34 | 0 | 100.00 |
| Illumipro-10 | negative | 3 | 0 | 100.00 |
| Other methods | negative | 8 | 0 | 100.00 |
| Total | | 92 | 0 | 100.00 |

Commentary H11

The sample did not contain Plasmodium, the result was negative.

V01 HIV Schnelltest

| HIV Rapid Test | Target Value | negative | positive | % Conform |
|-----------------------|---------------------|-----------------|-----------------|------------------|
| Determine HIV 1/2 | positive | 0 | 18 | 100.00 |
| Other methods | positive | 2 | 4 | 66.67 |
| Total | | 2 | 22 | 91.67 |